Literature DB >> 11841688

Non-lethal viral challenge of influenza haemagglutinin and nucleoprotein DNA vaccinated mice results in reduced viral replication.

R J Cox1, E Mykkeltvedt, J Robertson, L R Haaheim.   

Abstract

Influenza DNA vaccines have been widely studied in experimental animal models and protection documented after lethal viral challenge. In this study, we have investigated the humoral response after a non-lethal viral challenge of mice vaccinated with plasmids encoding the influenza haemagglutinin (HA) or nucleoprotein (NP) genes. BALB/c mice were immunized intramuscularly with three doses (100 microg) of HA, NP or backbone plasmid at 3-week intervals, or alternatively infected intranasally, before being challenged with homologous virus 13 weeks later. Mice were then sacrificed at weekly intervals and the antibody-secreting cell response was examined systemically (spleen and bone marrow) and in the respiratory tract (nasal associated lymphoid tissue (NALT) and lungs). Sera were collected after each dose of vaccine and at sacrifice and analyzed by ELISA, haemagglutination inhibition and virus neutralization assays. We found that previous viral infection apparently elicits sterilizing immunity. Vaccination with HA or NP DNA significantly reduced viral replication in the nasal cavity after viral challenge, however, increases in serum antibody titres were observed after challenge. Prior to challenge, specific antibody-secreting cells were observed in the systemic compartment after HA or NP DNA vaccination but were also found in the NALT after viral challenge. In conclusion, intramuscular DNA vaccination resulted in immunological memory in the systemic compartment, which was rapidly reactivated upon viral challenge.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11841688     DOI: 10.1046/j.1365-3083.2002.01015.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  11 in total

1.  A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus.

Authors:  Damian M Carragher; Denise A Kaminski; Amy Moquin; Louise Hartson; Troy D Randall
Journal:  J Immunol       Date:  2008-09-15       Impact factor: 5.422

2.  Quality and kinetics of the antibody response in mice after three different low-dose influenza virus vaccination strategies.

Authors:  Solveig Hauge; Abdullah Madhun; Rebecca Jane Cox; Lars Reinhardt Haaheim
Journal:  Clin Vaccine Immunol       Date:  2007-06-27

3.  HBV DNA vaccine with adjuvant cytokines induced specific immune responses against HBV infection.

Authors:  De-Wei Du; Zhan-Sheng Jia; Guang-Yu Li; Yong-Ying Zhou
Journal:  World J Gastroenterol       Date:  2003-01       Impact factor: 5.742

4.  Development of Lentiviral Vectors Pseudotyped With Influenza B Hemagglutinins: Application in Vaccine Immunogenicity, mAb Potency, and Sero-Surveillance Studies.

Authors:  Francesca Ferrara; Joanne Marie M Del Rosario; Kelly A S da Costa; Rebecca Kinsley; Simon Scott; Sasan Fereidouni; Craig Thompson; Paul Kellam; Sarah Gilbert; George Carnell; Nigel Temperton
Journal:  Front Immunol       Date:  2021-05-24       Impact factor: 7.561

5.  Evaluation of the sublingual route for administration of influenza H5N1 virosomes in combination with the bacterial second messenger c-di-GMP.

Authors:  Gabriel Kristian Pedersen; Thomas Ebensen; Ingrid Hjetland Gjeraker; Signe Svindland; Geir Bredholt; Carlos Alberto Guzmán; Rebecca Jane Cox
Journal:  PLoS One       Date:  2011-11-01       Impact factor: 3.240

6.  The mucosal and systemic immune responses elicited by a chitosan-adjuvanted intranasal influenza H5N1 vaccine.

Authors:  Signe C Svindland; Åsne Jul-Larsen; Rishi Pathirana; Solveig Andersen; Abdullah Madhun; Emanuele Montomoli; Inderjit Jabbal-Gill; Rebecca J Cox
Journal:  Influenza Other Respir Viruses       Date:  2011-07-12       Impact factor: 4.380

7.  Matrix-M adjuvanted virosomal H5N1 vaccine confers protection against lethal viral challenge in a murine model.

Authors:  Gabriel Pedersen; Diane Major; Sarah Roseby; John Wood; Abdullah S Madhun; Rebecca J Cox
Journal:  Influenza Other Respir Viruses       Date:  2011-05-09       Impact factor: 4.380

8.  A pilot study of the immune response to whole inactivated avian influenza H7N1 virus vaccine in mice.

Authors:  Arnt-Ove Hovden; Karl A Brokstad; Diane Major; John Wood; Lars R Haaheim; Rebecca J Cox
Journal:  Influenza Other Respir Viruses       Date:  2009-01       Impact factor: 4.380

9.  A study of Chitosan and c-di-GMP as mucosal adjuvants for intranasal influenza H5N1 vaccine.

Authors:  Signe C Svindland; Gabriel K Pedersen; Rishi D Pathirana; Geir Bredholt; Jane K Nøstbakken; Åsne Jul-Larsen; Carlos A Guzmán; Emanuele Montomoli; Giulia Lapini; Simona Piccirella; Inderjit Jabbal-Gill; Michael Hinchcliffe; Rebecca J Cox
Journal:  Influenza Other Respir Viruses       Date:  2012-11-21       Impact factor: 4.380

10.  A cell-based H7N1 split influenza virion vaccine confers protection in mouse and ferret challenge models.

Authors:  Rebecca J Cox; Diane Major; Solveig Hauge; Abdullah S Madhun; Karl A Brokstad; Mirjam Kuhne; Jon Smith; Frederick R Vogel; Maria Zambon; Lars R Haaheim; John Wood
Journal:  Influenza Other Respir Viruses       Date:  2009-05       Impact factor: 4.380

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.